Last reviewed · How we verify
Celecoxib, COX-2 inhibitor; oral
Celecoxib, COX-2 inhibitor; oral is a COX-2 inhibitor Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Treatment of osteoarthritis, rheumatoid arthritis, and acute pain, Management of primary dysmenorrhea.
Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain.
Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain. Used for Treatment of osteoarthritis, rheumatoid arthritis, and acute pain, Management of primary dysmenorrhea.
At a glance
| Generic name | Celecoxib, COX-2 inhibitor; oral |
|---|---|
| Sponsor | Pfizer |
| Drug class | COX-2 inhibitor |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Osteoarthritis, Rheumatoid Arthritis, Pain |
| Phase | Phase 2 |
Mechanism of action
This inhibition reduces prostaglandin production, leading to decreased inflammation and pain. Celecoxib's selectivity for COX-2 over COX-1 helps minimize gastrointestinal side effects associated with traditional NSAIDs.
Approved indications
- Treatment of osteoarthritis, rheumatoid arthritis, and acute pain
- Management of primary dysmenorrhea
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Nausea
Key clinical trials
- Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions (PHASE1)
- Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) (PHASE2)
- Preemptive Analgesia With Celecoxib for Acute Dental Pain Management (PHASE4)
- PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer (PHASE2)
- Adjunctive Celecoxib in Childhood-onset OCD Study (PHASE2)
- A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction (PHASE2)
- Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer (PHASE1)
- Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib, COX-2 inhibitor; oral CI brief — competitive landscape report
- Celecoxib, COX-2 inhibitor; oral updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Celecoxib, COX-2 inhibitor; oral
What is Celecoxib, COX-2 inhibitor; oral?
How does Celecoxib, COX-2 inhibitor; oral work?
What is Celecoxib, COX-2 inhibitor; oral used for?
Who makes Celecoxib, COX-2 inhibitor; oral?
What drug class is Celecoxib, COX-2 inhibitor; oral in?
What development phase is Celecoxib, COX-2 inhibitor; oral in?
What are the side effects of Celecoxib, COX-2 inhibitor; oral?
What does Celecoxib, COX-2 inhibitor; oral target?
Related
- Drug class: All COX-2 inhibitor drugs
- Target: All drugs targeting COX-2
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Osteoarthritis, Rheumatoid Arthritis, Pain
- Indication: Drugs for Treatment of osteoarthritis, rheumatoid arthritis, and acute pain
- Indication: Drugs for Management of primary dysmenorrhea
- Compare: Celecoxib, COX-2 inhibitor; oral vs similar drugs
- Pricing: Celecoxib, COX-2 inhibitor; oral cost, discount & access